WO2026042028 - HIGH-DENSITY VIRAL VECTOR FORMULATIONS AND USES THEREOF
National phase entry is expected:
Publication Number
WO/2026/042028
Publication Date
26.02.2026
International Application No.
PCT/IB2025/058400
International Filing Date
20.08.2025
Title **
[English]
HIGH-DENSITY VIRAL VECTOR FORMULATIONS AND USES THEREOF
[French]
FORMULATIONS DE VECTEURS VIRAUX À HAUTE DENSITÉ ET LEURS UTILISATIONS
Applicants **
CSL BEHRING LLC
Inventors
GILLE, Andreas
PATRIKAKIS, Margaret
Priority Data
63/685,016
20.08.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
USPTO
* |
| * | |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3726 | |
| EPO | Filing, Examination, Granting | 39865 | |
| Japan | Filing, Examination, Granting | 3447 | |
| South Korea | Filing, Examination, Granting | 4927 | |
| USA | Filing, Examination, Granting | 14710 |
Total:
66,675
Contact Us
Abstract[English]
The present disclosure relates generally to the manufacturing of gene therapy products and specifically to viral vector formulations comprising a high-density additive for increasing transduction of a cell with a viral vector and/or methods of transducing a cell with a viral vector in a cell culture and/or methods of increasing a viral vector transduction efficiency of a cell in a cell culture, the methods comprising using a viral vector formulation comprising a high-density additive, wherein the formulation has a density greater than the density of the cell culture medium.[French]
La présente invention concerne de manière générale la fabrication de produits de thérapie génique et spécifiquement des formulations de vecteurs viraux comportant un additif de haute densité pour augmenter la transduction d'une cellule avec un vecteur viral et/ou des procédés de transduction d'une cellule avec un vecteur viral dans une culture cellulaire et/ou des procédés d'augmentation de l'efficacité de transduction de vecteur viral d'une cellule dans une culture cellulaire, les procédés incluant l'utilisation d'une formulation de vecteur viral comportant un additif de haute densité, la formulation présentant une densité supérieure à la densité du milieu de culture cellulaire.